Orasis Pharmaceuticals is announcing the U.S. launch of Qlosi at SECO 2025 in Atlanta. The FDA approved low-dose, ...

Smith said that Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) is “very well tolerated” overall, and in clinical studies, it demonstrated positive real-world endpoints in functiona ...

Pilocarpine HCl 1%, 2%, 4%; oph soln; contains benzalkonium chloride. Local irritation, ciliary spasm, conjunctival injection, headache, induced myopia; transient night blindness may occur (esp.